

IL2-IRES-Venus-Luc

| | |
|---------------------|--|
| Nomenclature | C57BL/6Smoc- <i>IL2</i> ^{em1(Venus-Luci)Smoc} |
| Cat. NO. | NM-KI-18057 |
| Strain State | Embryo cryopreservation |

Gene Summary

| | | |
|---------------------------|-----------------------|------------------------------------|
| Gene Symbol IL2 | Synonyms | IL-2 |
| | NCBI ID | 16183 |
| | MGI ID | 96548 |
| | Ensembl ID | ENSMUSG00000027720 |
| | Human Ortholog | IL2 |

Model Description

an IRES-Venus Luci cassette was inserted into the IL2 gene stop codon site.

Research Application: Gene tracing

*Literature published using this strain should indicate: IL2-IRES-Venus-Luc mice (Cat. NO. NM-KI-18057) were purchased from Shanghai Model Organisms Center, Inc..

Validation Data

Hepa1-6 tumor growth




Fig1. Hepa1-6 tumor volumes in IL2-Venus-Luci reporter mice treated or not with anti-PD-1 mAb. Arrows indicate treatment days.




Fig2. In vivo imaging validation of Hepa1-6 tumors in IL2-Venus-Luci reporter mice treated or not with anti-PD-1 mAb.

In PBS treated group, the IL2 signal increased as the tumor development, which indicated an inflamed immune environment. In the PD1 mAb treated group, the IL2 signal is enhanced,

especially at day 21.




Fig3. IL2 signal in ventral position of IL2-Venus-Luci reporter mice.

IL2 signal from abdomen is higher in PD1 treated mice than control mice on day 21. The signal should be produced by immune cells in mesenteric lymph nodes.




Fig4. Tissue IL2 signal in the IL2-Venus-Luci reporter mice at termination.

Tumor draining lymph node(TDLN) from PD1 treated mice have significantly higher IL2 signal than control mice. While tumor and spleen showed lowered or comparable IL2 signal compared to control mice.

The data is provided by Crownbio.